Corticosteroid intravitreal implants

Developments in Ophthalmology

Volumn 51, Issue , 2012, Pages 122-133

  De Smet, Marc D ^a,b  

^a MIOS   (Switzerland)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

ANIMAL; ARTICLE; DRUG IMPLANT; HUMAN; TREATMENT OUTCOME; UVEITIS;

ANIMALS; DRUG IMPLANTS; GLUCOCORTICOIDS; HUMANS; TREATMENT OUTCOME; UVEITIS;

EID: 84860843097     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000336330     Document Type: Article

References (44)

1. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
2. Nguyen QD, Hatef E, Kayen B, Macahilig CP, Ibrahim M, Wang J, Shaikh O, Bodaghi B: A crosssectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology 2011;118:184-190.
3. Shen L, You Y, Sun S, Chen Y, Qu J, Cheng L: Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Ophthalmology 2010;117: 2365-2371.
4. Venkatesh P, Kumar CS, Abbas Z, Garg S: Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm 2008;16:217-223.
5. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids -new mechanisms for old drugs. New Engl J Med 2005;353:1711-1723.
6. de Bosscher K, Vanden Berghe W, Haegeman G: The interplay between the glucocorticoid receptor and nuclear factor-αb or activator protein-1: molecular mechanisms for gene repression. Endoc Rev 2003;24:488-522. (Pubitemid 37059110)
7. Edelman JL: Differentiating intraocular glucocorticoids. Ophthalmologica 2010;224:25-30.
8. McKenzie AW, Stoughton RB: Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:608-610.
9. Kelly HW: Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allerg Asthma Immunol 2003;91:326-334.
10. Nehme A, Lobenhofer E, Stamer WD, Edelman J: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics 2009; 2:58.
11. Fan BJ, Wang DY, Tham CC, Lam DS, Pang CP: Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. Invest Ophthalmol Vis Sci 2008;49:1886-1897.
12. Wenzel A, Grimm C, Seeliger MW, Jaissle G, Hafezi F, Kretschmer R, Zrenner E, Remé CE: Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 2001;42:1653-1659. (Pubitemid 32520761)
13. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R: Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Invest Ophthalmol Vis Sci 2009; 50:4847-4857.
14. Valamanesh F, Berdugo M, Sennlaub F, Savoldelli M, Goumeaux C, Houssier M, Jeanny JC, Torriglia A, Behar-Cohen F: Effects of triamcinolone acetonide on vessels of the posterior segment of the eye. Mol Vis 2009;15:2634-2648.
15. Torriglia A, Valamanesh F, Behar-Cohen F: On the retinal toxicity of intraocular glucocorticoids. Biochem Pharm 2010;80:1878-1886.
16. de Smet MD, Julian K: The role of steroids in the management of uveitic macular edema. Eur J Ophthalmol 2011;21:51-55.
17. Chang-Lin J-E, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang K-M, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF: Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011;52:4605-4609.
18. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D: Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80-86.
19. Schindler RH, Chandler DB, Thresker R, Machemer R: The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417. (Pubitemid 12143608)
20. Lee S, Ghosn C, Yu Z, Zacharias LC, Kao H, Lanni C, Abdelfattah N, Juppermann B, Csaky KG, D'Argenio DZ, Burke JA, Hughes PM, Robinson MR: Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci 2010;51: 2135-2138.
21. Doft B, Weiskopf J, Nilsson-Ehle I, Wingard L Jr: Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 1985;92: 1601-1605. (Pubitemid 16203728)
22. Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P: Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107:2024-2033.
23. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA: Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharm Ther 2004;20:269-275. (Pubitemid 38849806)
24. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T: Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirtyfour-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027. (Pubitemid 43795240)
25. Perkins SL, Gallemore RP, Yang CH, Guo H, Ashton P, Jaffe GJ: Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye. Retina 2000;20:514-519. (Pubitemid 32001527)
26. Kane FE, Burdan J, Cutino A, Green KE: Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2006;5:1039-1046.
27. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F: Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117: 1393-1399, e1393.
28. Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, Wang NS, Csaky KG: Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 2004;45:2722-2731. (Pubitemid 38998870)
29. Li SK, Lizak MJ, Jeong EK: MRI in ocular drug delivery. NMR Biomed 2008;21:941-956.
30. Thakur A, Kadam R, Kompella UB: Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Archiv Ophthalmol 2011;129:914-920.
31. James ER: The etiology of steroid cataract. J Ocul Pharmacol Ther 2007;23:403-420. (Pubitemid 350202485)
32. Szabó V, Borgulya G, Filkorn T, Majnik J, Bányász I, Nagy ZZ: The variant n363s of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy. Mol Vis 2007;13:659-666. (Pubitemid 46712052)
33. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon Y-H, Jacques M-L, Jiao J, Li X-Y, Whitcup SM: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146, e1133.
34. Boyer DS, Faber DJ, Gupta SK, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM, for the Ozurdex Champlain Study Group: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31: 915-923.
35. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li X-Y, Cui H, Whitcup SM, for the Ozurdex HSG: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-553.
36. London NJ, Chiang A, Haller JA: The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011;28:351-366.
37. Pearson PA, Comstock TL, Ip MS, Callanan D, Morse LS, Ashton P, Levy B, Mann ES, Eliott D: Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118:1580-1586.
38. Jain N, Stinnett SS, Jaffe GJ: Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion thirty-sixmonth results. Ophthalmology 2012;119:132-137.
39. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL: Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-1201.
40. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW: Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010;117:567-575.
41. Goldstein DA, Godfrey DG, Hall AJH, Callanan DG, Jaffe GJ, Pearson A, Usner DW, Comstock TL: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125:1478-1485. (Pubitemid 350106679)
42. Yeh S, Cebulla DM, Witherspoon SR, Emerson GG, Emerson MV, Suhler EB, Albini TA, Flaxel CJ: Management of fluocinolone implant dissociation during implant exchange. Arch Ophthalmol 2009; 127:1218-1221.
43. Wan W, Stewart JM: Use of a high infusion rate to prevent posterior dislocation of fluocinolone acetonide implant during surgical removal. Ocul Immunol Inflamm 2011;19:214-215.
44. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE: Randomized comparison of systemic antiinflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011;118:1916-1926.